Equities Analysts Set Expectations for TSE:ONC Q1 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Oncolytics Biotech in a report issued on Friday, April 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.04) per share for the quarter, up from their prior estimate of ($0.09). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at ($0.10) EPS.

Oncolytics Biotech Trading Down 1.3%

Shares of TSE:ONC opened at C$14.90 on Tuesday. The company has a current ratio of 2.88, a quick ratio of 8.86 and a debt-to-equity ratio of 14.58. The company has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The business has a 50 day moving average of C$14.90 and a two-hundred day moving average of C$14.90. Oncolytics Biotech has a 12-month low of C$0.44 and a 12-month high of C$2.08.

Insider Buying and Selling at Oncolytics Biotech

In other Oncolytics Biotech news, insider Andrew P. Aromando bought 29,600 shares of Oncolytics Biotech stock in a transaction dated Wednesday, February 11th. The stock was acquired at an average cost of C$1.18 per share, with a total value of C$34,928.00. Following the purchase, the insider directly owned 55,100 shares in the company, valued at C$65,018. This represents a 116.08% increase in their position. Also, insider Jared Ryan Kelly bought 29,500 shares of Oncolytics Biotech stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the completion of the purchase, the insider owned 109,000 shares in the company, valued at approximately C$126,440. This trade represents a 37.11% increase in their ownership of the stock. Over the last quarter, insiders acquired 289,232 shares of company stock worth $335,760. 3.82% of the stock is currently owned by corporate insiders.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.